Hold the Presses is your online newsportal en brings press releases from around the world. Journalists can use it for free, although it is their responsibilty to check the news. Hold the Presses is in no way responsible for the content of the press releases, the Sender is. We hope you enjoy reading the news we bring you on this website. If a message is published that is not acceptable, we apologize. Please contact us and we will remove the message as soon as possible.

Friday, 15 September 2017

Skåne University Hospital Becomes First Clinic in Sweden To Use Acarix CADScor®System For Early Rule-Out Of Coronary Artery Disease

Acarix AB    

Published: 08:00 CEST 15-09-2017 /GlobeNewswire /Source: Acarix AB / : ACARIX /ISIN: SE0009268717

Skåne University Hospital Becomes First Clinic in Sweden To Use Acarix CADScor®System For Early Rule-Out Of Coronary Artery Disease

Press release      
 
Malmö, September 15, 2017 
 
Skåne University Hospital Becomes First Clinic in Sweden To Use Acarix CADScor®System For Early Rule-Out Of Coronary Artery Disease 
The company's roll-out program on track as interest grows following international launch at ESC conference in Barcelona 
Acarix AB (publ) ("Acarix") today announced that the Cardiology Department at Skåne University Hospital in Lund will be the first Swedish Clinic using CADScor®System for non-invasive, non-radiation acoustic ruleout of Coronary Artery Disease (CAD). A recently presented study at the American College of Cardiology (ACC) 2017 Annual Scientific Meeting showed that CADScor®System rules out CAD with 97% negative predictive value.  
 
The CADScor®System combines acoustic detection of turbulent arterial flow and myocardial movement with advanced algorithms in a portable device to provide a patient specific CAD-score in less than 10 minutes.  
 
Sweden has a proud heritage of excellence in cardiovascular research and is already in the forefront when it comes to Coronary Artery Disease. The decision to introduce CADScor®System was explained by Professor David Erlinge, Professor in Cardiology at Lund University and Head of the Cardiology Department at Skåne University Hospital in Lund: "In patients with suspected CAD, applying non-invasive methods should always be step one. Current non-invasive methods such as stress tests e.g. exercise ECG, are time-consuming and they often do not produce sufficient information for an accurate diagnosis. Thus, many patients are referred to further, invasive tests either confirming the suspicion of CAD or, in many cases demonstrating that their symptoms are unrelated to CAD. We therefore look forward to introducing this easy to use and non-invasive diagnostic device to rule out CAD with high accuracy for the benefit of both patients and healthcare. The aim is to ensure that only the patients that need to be referred to further, appropriate diagnostic tests get them and that patients with symptoms unrelated to CAD do not." 
 
Acarix CEO Søren Rysholt Christiansen commented: "We are very pleased to see the CADScor®System being introduced at the Cardiology Department in one of Sweden's largest hospitals, Skåne University Hospital in Lund. This purchase order continues the international expansion of CADScor®System and marks yet another milestone in our commercialization strategy. We look forward to following the experience gained in Lund in anticipation of future reimbursement and launch in the rest of the Swedish public-sector market.  
 
Contacts:  
Acarix 
Søren Rysholt Christiansen, CEO, E-mail: dksrc@acarix.com Phone: +45 2777 1112 
 
 
 
This information is information that Acarix AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation 596/2014. The information was submitted for publication, through the agency of the contact person set out above, at 08:00 CEST on September 15, 2017. 
 
Notes to editors: Acarix, CADScor®System and cardiac sound measurement Acarix was established in 2009, and since 2010 investors SEED Capital (DK) and Sunstone Life Science Ventures (DK) have supported it towards market introduction. Acarix was listed on Nasdaq First North Premier in 2016 and has attracted a highly-experienced management team having held senior positions in international medical device companies - CEO Søren Rysholt Christiansen with Cook Medical, GN ReSound, and ELOS Medtech. 
Acarix's CADScor®System is based on engineering excellence in sound recording and signal processing. It has long been known that both cardiac contraction movement and turbulent flow can generate sound. Contraction related sounds are in lower frequency, whereas turbulent sounds in the streaming blood caused by partial obstruction (stenosis) in the coronary arteries are of higher frequencies. The detection of these murmurs is delicate, since the energy of the murmurs is very weak. Detecting and recording the coronary murmurs requires not only an advanced sensor but also means for proper attachment to the skin above the heart to optimize the recorded signal and to avoid external noise.  
The Acarix CADScor®System has been designed to be an all-in-one system in the sense that the heart signal will be recorded, processed, and displayed as a patient specific score, the CAD-score, on the device screen. The CADScor®System contains the necessary electronics to instruct professionals during use and to guide through the recording periods. The system also contains a docking station for daily qualification of the sensor. Further the system integrates with an adhesive patch for locking the sensor to a fixed position above the heart during the recording.  
See more at www.acarix.com. Press kit: http://www.acarix.com/about-us/press-downloads/.  
 


20170915 Press Release First Swedish Customer_UK



This announcement is distributed by Nasdaq Corporate Solutions (One Liberty Plaza, 165 Broadway, New York, NY 10006. Tel: +1 212 401 8700. www.nasdaqomx.com) on behalf of NASDAQ OMX Corporate Solutions clients. Source: Acarix AB, Word Trade Center Skeppsgatan 19, Malmö 211 11, Sweden
If you would like to unsubscribe and stop receiving these e-mails click here.